LCA-0391

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameLCA-0391
Drug Alias NameLCA-0391
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)
Mechanisms of ActionMuscle, skeletal receptor tyrosine-protein kinase modulators
TargetsMuscle, skeletal receptor tyrosine-protein kinase
Therapy Area/IndicationsAsperger SyndromeMyasthenia Gravis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLycia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLycia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAsperger SyndromeMyasthenia Gravis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A